The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis

被引：30
作者：
AbuHilal, Mohn'd [1 ,2 ]
Walsh, Scott [1 ,2 ]
Shear, Neil [1 ,2 ]
机构：
[1] Sunnybrook Hlth Sci Ctr, Div Dermatol, Dept Med, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY | 2016年 / 20卷 / 06期
关键词：
IL-17; psoriasis; secukinumab; ixekizumab; brodalumab; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; IN-VIVO IMPLICATIONS; DOUBLE-BLIND; TH17; CYTOKINES; T-CELLS; INTERLEUKIN (IL)-22; PHASE-2; TRIAL; NAIL LESIONS; OPEN-LABEL; SECUKINUMAB;
D O I：
10.1177/1203475416651605
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Background: Major advances have been made in the understanding of the pathophysiology of psoriasis. Objectives: The authors review the role of interleukin (IL) 17 in the pathogenesis of psoriasis and provide updates on approved and investigational therapies targeting IL-17 and the IL-17 receptor. Methods: A PubMed search was performed for relevant literature. Conclusion: The IL-23/Th17 signaling pathway (including IL-17) plays a central role in the pathogenesis of psoriasis. Biologic agents that block IL-17 (secukinumab and ixekizumab) or its receptor (brodalumab) are effective and safe for the treatment of psoriasis.
引用
收藏
页码：509 / 516
页数：8
相关论文
共 61 条
[1]   Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial [J].
Augustin, M. ;
Abeysinghe, S. ;
Mallya, U. ;
Qureshi, A. ;
Roskell, N. ;
McBride, D. ;
Papavassillis, C. ;
Gelfand, J. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (04) :645-649
[2]  
Balzola F, 2012, INFLAMM BOWEL DIS MO, V13, P27
[3]   Brodalumab-an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis [J].
Bauer, Erin ;
Lucier, Jessica ;
Furst, Daniel E. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (06) :883-893
[4]   Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) [J].
Blauvelt, A. ;
Prinz, J. C. ;
Gottlieb, A. B. ;
Kingo, K. ;
Sofen, H. ;
Ruer-Mulard, M. ;
Singh, V. ;
Pathan, R. ;
Papavassilis, C. ;
Cooper, S. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (02) :484-493
[5]  
Blauvelt A, PATHOPHYSIOLOGY PSOR
[6]   Etiology and Pathogenesis of Psoriasis [J].
Boehncke, Wolf-Henning .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (04) :665-+
[7]   New insights of T cells in the pathogenesis of psoriasis [J].
Cai, Yihua ;
Fleming, Chris ;
Yan, Jun .
CELLULAR & MOLECULAR IMMUNOLOGY, 2012, 9 (04) :302-309
[8]   Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis Pathogenesis [J].
Carrier, Yijun ;
Ma, Hak-Ling ;
Ramon, Hilda E. ;
Napierata, Lee ;
Small, Clayton ;
O'Toole, Margot ;
Young, Deborah A. ;
Fouser, Lynette A. ;
Nickerson-Nutter, Cheryl ;
Collins, Mary ;
Dunussi-Joannopoulos, Kyri ;
Medley, Quintus G. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (12) :2428-2437
[9]   Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis [J].
Chen, Yan ;
Qian, Tian ;
Zhang, Dongmei ;
Yan, Heng ;
Hao, Fei .
IMMUNOTHERAPY, 2015, 7 (09) :1023-1037
[10]   Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy [J].
Coimbra, S. ;
Oliveira, H. ;
Reis, F. ;
Belo, L. ;
Rocha, S. ;
Quintanilha, A. ;
Figueiredo, A. ;
Teixeira, F. ;
Castro, E. ;
Rocha-Pereira, P. ;
Santos-Silva, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (06) :1282-1290
1234567